Drug Profile
Research programme: melanotransferrin conjugated therapeutics - biOasis/AstraZeneca
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; biOasis Technologies
- Class Drug conjugates
- Mechanism of Action Biological transport stimulants; Transferrin-binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (Parenteral, Injection)
- 12 May 2015 Preclinical trials in Neuropathic pain in Canada (Parenteral)
- 12 May 2015 Preclinical pharmacodynamics and pharmacokinetics data in Neuropathic pain released by biOasis Technologies